Details for Patent: 11,020,387
✉ Email this page to a colleague
Which drugs does patent 11,020,387 protect, and when does it expire?
Patent 11,020,387 protects ZUBSOLV and is included in one NDA.
This patent has fifty-one patent family members in thirty-two countries.
Summary for Patent: 11,020,387
| Title: | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
| Abstract: | There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain. |
| Inventor(s): | Andreas Fischer |
| Assignee: | Edenbridge Pharmaceuticals LLC |
| Application Number: | US17/032,934 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,020,387 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
| Patent landscape, scope, and claims: |
More… ↓ |
Drugs Protected by US Patent 11,020,387
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Edenbridge Pharms | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-005 | Jun 4, 2015 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | USE OF ZUBSOLV FOR TREATMENT OF OPIOID DEPENDENCE | ⤷ Start Trial | |||
| Edenbridge Pharms | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-002 | Jul 3, 2013 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | USE OF ZUBSOLV FOR TREATMENT OF OPIOID DEPENDENCE | ⤷ Start Trial | |||
| Edenbridge Pharms | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-003 | Dec 11, 2014 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | USE OF ZUBSOLV FOR TREATMENT OF OPIOID DEPENDENCE | ⤷ Start Trial | |||
| Edenbridge Pharms | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-004 | Dec 11, 2014 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | USE OF ZUBSOLV FOR TREATMENT OF OPIOID DEPENDENCE | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,020,387
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2012311293 | ⤷ Start Trial | |||
| Australia | 2013245546 | ⤷ Start Trial | |||
| Brazil | 112014006356 | ⤷ Start Trial | |||
| Canada | 2834327 | ⤷ Start Trial | |||
| Chile | 2014000575 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
